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Celiac disease (CD) has taken center stage in the public eye, now afflicting 1:250 
to 1:100 people in the United States.  While CD etiology is most certainly polyfactorial, 
stemming from genetic, environmental, and immunologic factors, a causative agent of 
CD has been identified as a malfunctioning tissue transglutaminase (tTG).  A ubiquitous 
enzyme that has numerous roles body-wide, tTG most notably digests small peptides in 
the jejunum.  When tTG in the brush border of the small intestine comes in contact with 
gliadin, the immunoreactive peptide segment within gluten, tTG forms an irreversible 
complex that signals for an immune and inflammatory response.  Current treatment 
options are limited only to strict adherence to a gluten free diet—a lifestyle that is 
incompatible with the majority of the American population. 
I propose a radical treatment alternative, involving the silencing of the gene 
responsible for the faulty tTG.  Using ß-cyclodextrin nanopolymers designed by Davis, et 
al. as a delivery vehicle, siRNA will be injected intravenously and specifically target 
small intestinal cells expressing tTG. 
An exemplary case study of a 23 year old female is included in order to illustrate 
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Once considered a rare affliction, Affecting only 1:10,000 people nationally 
(Ciclitira, 2004), celiac disease (CD), also known as celiac sprue, wheat intolerance, and 
gluten intolerance, has taken center stage in the public eye.  Fifty years ago, Celiac 
disease was only seen in its most severe stages, with patients suffering extreme weight 
loss, nutrient malabsorption due to brush border blunting and small intestinal 
architectural disfigurement, chronic diarrhea, insurmountable fatigue and irritability, and 
a host of other problems.  However, symptoms of CD begin very mildly, if at all present, 
and take years to develop.  Today’s hospitals rarely treat individuals with irreparable 
intestinal damage and are now seeing a greater stratification of patients suffering milder 
symptoms.  Thanks to advancements in antibody screenings, it is apparent that the actual 
number of people suffering from CD is closer to 1:250 to 1:100 (Presutti, Cangemi, 
Cassidy, & Hill, 2007), with evidence increasingly pointing to levels of 1:100 or greater 
(Van Heel & West, 2006). 
The causative agent of CD is a malfunctioning tissue transglutaminase (tTG), a 
ubiquitous enzyme that has numerous roles body-wide, including small peptide digestion 
in the jejunum.  When tTG in the brush border of the small intestine comes in contact 
with gliadin, the immunoreactive peptide segment within gluten, tTG forms an 
irreversible complex that signals for an immune and inflammatory response.  This 
inflammation in response to the tTG-gluten complex eventually leads to disastrous 
disfigurement of the small intestine if left untreated. 
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Despite our increased diagnostic capabilities, treatment has remained completely 
unaltered since its original documentation in 1954 by J. W. Paulley.  The only treatment 
currently available to those that are gluten intolerant is a gluten-free diet, a lifestyle that 
provides as many problems as it solves.  A large portion of the alleles coding for gluten 
intolerance can be traced back to European origins, whose culture (coinciding with our 
own national roots and culture), ironically, bases a substantial portion of their diet on 
gluten based foods such as wheat bread, pasta, rye, barley, and oats.  Maintenance of a 
gluten free diet, while providing vast relief of all symptoms, is extremely difficult in 
current US culture, especially considering as little as 10mg of gluten may trigger an 
immune response (Hischenhuber et al., 2006).  Therefore, I propose a radical treatment 
alternative, involving the silencing of the gene responsible for the faulty tTG.  Using ß-
cyclodextrin nanopolymers designed by Davis, et al. as a delivery vehicle, siRNA will be 
injected intravenously and specifically target small intestinal cells expressing tTG.  While 
systemic knockout of tTG has shown to produce phenotypically normal organisms, 
localizing tTG knockout to the causal intestinal cells will increase the efficacy of the 
siRNA uptake to target cells and limit the possibility for still unforeseen phenotypic 
disturbances.  With this treatment, I hope to provide those who suffer from CD with a 
higher quality of life by alleviating their symptoms while maintaining their dietary 
options. 
Symptomology 
Celiac Disease (CD) presents a wide range of symptoms, with severity varying 
greatly from case to case.  Gastrointestinal discomfort, nutrient malabsorption, 
generalized weakness and lethargy, anemia, and intestinal mucosal damage are 
3 
 
commonly seen.  These symptoms only occur after ingesting gluten proteins found in 
wheat, barley, and rye.   
CD is characterized by intestinal mucosal damage that increases with the severity 
of the illness.  Paulley noted as early as 1954 variable stage inflammation in the form of 
increased lymphocyte and plasma cell infiltrate and increased intraepithelial 
lymphocytes.  While the mucosa normally contains plasma and T-cells, their number, 
along with those of newly infiltrated granulocytes, increases drastically in patients with 
CD.  Inflammation is generally localized to the lamina propria of the upper 60% of the 
small intestine. Crypt hyperplasia is seen in later stages with partial to complete intestinal 
villous atrophy in the most severe cases (Oberhuber, Granditsch, & Vogelsang, 1999).  
Atrophy extent, diagnostic quantification of infiltrate levels and substantial changes in 
small-intestine architecture will be discussed later.   
This “blunting” of the small-intestinal brush border can often lead to nutrient 
malabsorption, especially fat-soluble vitamins, such as Vitamin A, D, E, and K.  Anemia 
may also be seen from poor iron uptake or via the poor uptake of Vitamin B12 and folic 
acid (Di Sabatino & Corazza, 2009).  As a result, many patients suffering from CD 
complain of weakness, lethargy and fatigue, and in children, failure to thrive (“Childhood 
disease and disorder,” 2012). 
 Gastrointestinal discomfort is the most widely reported symptom of CD, 
including, but not limited to, bloating, flatulence, indigestion, abdominal distension, and 
diarrhea.  Bowel movements may be frequent and extremely malodorous.  In general, the 
symptoms of CD are highly similar to irritable bowel syndrome (IBS); the physician 
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should take care to note changes in symptomology with changes in diet when taking 
patient history (“Celiac disease,” 2012). 
 Celiac disease will often remain untreated if it presents asymptomatically with 
regards to the GI tract.  Dermatitis herpetiformis, osteoporosis, amenorrhea, and 
miscarriage are linked to CD if certain genetic risk factors are present (“Celiac disease,” 
2012; Presutti et al., 2007).  Severe untreated celiac disease increases the patient’s risk of 
developing adenocarcinoma or intestinal lymphoma.  Pregnant women may also give 
birth to infants with congenital defects (“Celiac disease,” 2012). 
Pathology 
Genetic factors 
The HLA-DQ family is an MHC class II antigen-presenting receptor.  HLA-DQ is 
involved primarily in self/non-self recognition.  However, through an unknown 
mechanism, HLA-DQ loses specificity for antigen-producing self-cells in certain 
individuals.  This loss of specificity generally causes autoimmune dysfunction, as is the 
case in CD.  HLA-DQ is a dimer of an α and ß chain, of which the body normally 
produces two variants each, totaling to four isoforms per person.  Eight isoforms have 
been discovered (HLA-DQ2, HLA- DQ4-9, and Factor XIII A).  The most common 
isoforms are HLA-DQ2 and HLA-DQ5.  95% of all individuals with CD have either the 
HLA-DQ2 or the HLA-DQ8 isoform (Klitz et al., 2003).  These proteins are one of the 
causative agents of celiac disease for they have the ability to bind the tTG-gliadin 
complex more tightly than other isoforms, with a near-100% probability of causing T-cell 
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activation and the subsequent immune response in the intestinal mucosa (Van Heel & 
West, 2006).  
 The α and ß chains are encoded on chromosome six by genes HLA-DQA1 and 
HLA-DQB1, respectively.  DQ isoforms are caused by single nucleotide polymorphisms 
(SNP’s) which, when causing a non-silent mutation, alter the peptide-binding region that 
presents foreign particles to T-cells.  In the case of CD, DQ2 isoforms have large overlap 
with tTG-gliadin protein complexes and initiate the immune response upon binding. 
 The vast majority of people with the DQ2 isoform possess a DQ2 heterodimer—a 
haplotype of the two adjacent alleles DQA1*0501, coding for the α
5
 chain species, and 
the DQB1*0201 allele, coding for the ß
2
 chain species.  While only one copy is normally 
inherited, if an individual receives a copy from both parents, the risk for developing CD 




Figure 1. HLA-DQ2 structure with bound α-gliadin.  The α chain is yellow, the ß chain is 
blue, and α-gliadin is red.  Retrieved from the Protein Database, Accession Code 1S9V.  
It should be noted that the DQ2 and DQ8 isoforms are neither necessary nor 
sufficient to cause CD.  Approximately 25% of individuals who have inherited one or 
both isoforms do not develop CD, while 5% of patients with CD have neither isoform.  
This suggests that CD is caused by multiple factors and not solely by inherited genetics 
(Hadithi, Blomberg, Crusius, Bloemena, & Kostense, 2007; van Heel & West, 2006). 
Immunologic factors 
The development of CD is completely dependent upon two factors: the dietary 
intake of gluten peptides and the presence of a faulty tTG.  Specifically, plant storage 
proteins rich in proline and glutamine residues (often called prolamins) which resist 
enzymatic proteolysis are the causal peptides.  Looking at the α-gliadin protein in wheat, 
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an 18mer hydrophobic sequence is followed by a series of proline residues which prevent 
proper binding to the active site of enzymes of the pancreas, stomach, and small intestine 
(Van Heel & West, 2006).   
Undigested α-gliadin 18mer sequences (amino acids 31-49) act as an innate 
immune response stimulator to cause the release of interleukin-15 from enterocytes (Van 
Heel & West, 2006).  Upon apical exposure to gliadin, CXCR3 receptors bind the peptide 
and initiate an intracellular cascade.  Intestinal epithelia secrete zonulin, a protein that 
causes tight junction disassembly.  While still unclear, it is possible that zonulin control is 
poorly regulated in patients with CD (Berti, Tommasini, & Goldblum, 2000). Once 
epithelial tight junctions have been disassembled, large proteins normally unable to pass 
the plasma membrane, such as gliadin, pass through the brush border and into the lamina 
propria (Green & Cellier, 2007).  Gliadin is recognized as a foreign body and stimulates 
the release of the cytokine interleukin-15 (IL-15).  The paracrine signaling of IL-15 acts 
on numerous cells proximal to the “infected” enterocyte.  The expression of MHC class I 
polypeptide-related sequence A (MICA), a cell surface protein used to signal natural 
killer cells and T-cells, is increased in the enterocytes containing gliadin.  The production 
of the NKG2D cell surface receptor on intraepithelial lymphocytes (IEL) is also 
upregulated.  When the NKG2D receptor of an IEL binds MICA proteins, the 
compromised enterocytes are immediately destroyed (Van Heel & West, 2006).  It is 
highly probable that this self-targeting of enterocytes post-gliadin entry weakens the 
intestinal epithelium enough to allow extensive gliadin invasion of the lamina propria. 
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Gluten peptides may also cause T-cell activation through irreversible crosslinking 
to tissue transglutaminase (tTG).  The enzyme-peptide complex has a high affinity for the 
HLA-DQ2 protein, which presents the complex to CD4+ T-cells specific to gluten to 
initiate the adaptive immune response (Van Heel & West, 2006).  tTG is a calcium 
dependent intracellular enzyme with roles in structural reinforcement of the matrix, 
preparation for apoptosis, and cellular differentiation (Griffin, Casadio, & Bergamini, 
2002).  When stressed by inflammation, infection, or mechanical force, tTG is released 
from the cell to the extra cellular matrix (ECM) and binds to cellular scaffolding to 
increase support.  However, when the host cell becomes fatally damaged, tTG is activated 
intracellularly and begins a signaling cascade for apoptosis (Schuppan, 2000).  Tissue 
transglutaminase forms a proteolysis-resistant intramolecular isopeptidyl bond between 
the epsilon-amino group of a lysine in its active site with the gamma-carboxyamide group 
of a glutamine residue within gluten.  Three key glutamine residues are also deamidated 
to glutamate, increasing the negative charge of the complex and increasing its binding 
affinity with HLA-DQ2 (Schuppan, 2000; van Heel & West, 2006).   
Comparatively, tTG-gliadin complexes are capable of causing significantly more 
inflammation than local responses to gliadin entry alone.  While the inflammatory 
response elicited through the tight junction disassembly cascade only activates local 
IEL’s in the brush border, tTG-gliadin complexes have the ability to generate a system-
wide immune response through CD4+ T-cell activation and subsequent B-cell activation.  
Gliadin peptides, now in the lamina propria, bind irreversibly to antigen-presenting cells 
with the HLA-DQ receptor.  Once bound, the complex signals T-cell infiltration and 
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targeted cell destruction.  Activated B-cells begin producing antigliadin, antiendomysial, 
and anti-tTG antibodies (Green & Cellier, 2007).  Thus, inflammation from the adaptive 
immune response occurs in four ways: HLA-DQ signaled infiltration of T-cells, T-cell 
destruction of HLA-DQ-gliadin enterocytes, antibody signaled T-cell infiltration to any 
intestinal tissue presenting gliadin peptides or tTG, and finally T-cell destruction of 
antibody bound cells or peptides. It is this system-wide signaling that is the major cause 
of granulocyte infiltration into the affected tissues, inflammation, and consequently 
villous atrophy and crypt hyperplasia.  For this reason, many consider the tTG-gliadin 
complex to be the primary source of inflammation, rather than the tight junction 
disassembly alone (Ciclitira, 2004; Green & Cellier, 2007; van Heel & West, 2006).  
Elimination of immune system activation by tTG would prevent the overwhelming 




Figure 2.  Mechanism of immune system activation upon gliadin exposure.  Gliadin 
activates the innate immune system in the epithelium and the adaptive immune system in 
the lamina propria.  Gliadin damages the invaded epithelial cells, releasing IL-15 and 
activating nearby IEL’s.  Binding to HLA-DQ2 receptors on cells in the lamina propria 
activates the adaptive immune response, triggering T-cell mediated destruction, B-cell 
activation and antibody formation (Green & Cellier, 2007). 
 
Diagnosis 
 The simplest—and often only—method of diagnosis and treatment still remains to 
be one of the most reliable: strict adherence to a gluten free diet.  If the patient is indeed 
suffering from gluten intolerance and has not suffered irreparable villous atrophy, 
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serological markers, body weight, energy levels, and miscellaneous symptomology such 
as dermatitis herpetiformis should return to normal after several months without gluten.  
Nonetheless, while active symptomology may have disappeared, the patient may still 
suffer from underlying mucosal damage and should be further examined to determine 
present health risks. 
Traditional methods of diagnosis may be categorized by one of three exams: 
serological exams, biopsies of the proximal small intestine, and endoscopies.  The least 
intrusive and most cost effective, visualization of anti-tTG antibodies in the blood via an 
ELISA assay should be done first.  However, positive results for anti-tTG antibodies are 
not sufficient for a conclusive diagnosis.  Jejunal biopsy and classification based on the 
Marsh Scale edited by Oberhuber remains the “gold standard” for a positive diagnosis 
(Ciclitira, 2004).  Oberhuber’s modern classification rates the disease based on its 
severity as Type 1, Type 2, or Type3a-3c. 
Table 1.  Modified Marsh Classification for pathological diagnosis of celiac disease.  
As the general severity of Celiac disease has decreased over the past fifty years, it was 
necessary for greater differentiation between less severe manifestations of CD.  
Oberhuber’s revisions provide for greater specificity between patients with milder 





Video capsule endoscopy (VCE) is much preferred over traditional endoscopy as 
it is minimally invasive and requires far fewer hospital resources and man hours while 
providing high quality visual documentation of the entire digestive tract.  Clear markers 
indicative of villous atrophy include scalloping of the intestinal wall, mosaic-like 
patterning, and micronodularity of the villi (Akin & Ersoy, 2012). 
Treatment 
The only recognized and accepted treatment for celiac disease remains the 
application of a gluten free diet.  Adherence to the diet must be complete; gluten is 
capable of stimulating an immune response at levels as low as 10mg per day 
(Hischenhuber et al., 2006).  Gluten’s high toxicity makes it absolutely necessary to 
avoid any gluten intake to allow the small intestine to reduce in inflammation and the 
healing process to reach its maximum potential.  Depending on the extent of the mucosal 
damage, two to six months may pass before noticeable improvement in villous structure 
occurs.  The difficulty for most people to faithfully remain on this diet for life and their 
reported lowered quality of life from the severe restrictions on their eating choices begs 
for new treatment options.  Celiac disease has been treated in the same manner for the 
past sixty years without innovation.  These issues demand a novel treatment method 
capable of eliminating symptoms while maintaining the patient’s quality of life.  Gene 
therapy, while used as a treatment almost exclusively in the realm of cancer, could 
potentially be the curative agent for those suffering from CD.  By silencing the gene 
coding for tTG, it would be possible to eliminate all symptoms at their source while still 
retaining the ability to ingest gluten. 
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Overview of tTG Function 
Before engaging any patient in experimental treatments, it is vitally necessary that 
the physician ensures that a positive diagnosis is made.  While evidence supports the 
functionality and complete lack of immunogenicity in the treatment plan described 
below, gene therapy treatments are not to be trifled with and should only be used when 
serious health concerns are of issue.   
Table 2.  Summary of functions of known transglutaminase isoforms (Griffin et al., 
2002). Eight isoforms of transglutaminase have been identified in humans; type 2 is of 
extreme importance to CD, especially its role in protein adhesion during periods of 
cellular stress.  
Identified tTG isoform Synonym names Prevalent Function 
Factor XIII A Fibrin Stabilizing Factor Blood clotting and wound 
healing 
Type 1 Keratinocyte TG Cell envelope formation in 
keratinocyte differentiation 




Type 3 Epidermal TG Cell envelope formation 
during terminal keratinocyte 
differentiation 
Type 4 Prostate TG Reproductive function, 
semen coagulation 
Type 5 TG X Epidermal differentiation 
Type 6 TG Y Not characterized 
Type 7 TG Z Not characterized 
 
Type 2 tissue transglutaminase (tTG) plays a redundant or non-vital role in the 
regulation of apoptosis, cell differentiation, and matrix stabilization. Genetic encoding for 
each isoform seems to arise from independent genes rather than from alternative splicing.  
Tissue transglutaminase was isolated to chromosome 20q12 while Factor XIII A and type 
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1 TG were isolated to chromosomes 6p24-25 and 14q11.2, respectively (Gentile, Davies, 
& Baldindi, 1994). 
 Regarding apoptosis specifically, tTG has been shown to have roles during 
development and differentiation in interdigital formation, implantation of the fertilized 
embryo in the uterus, and mammary gland regression (Melino & De Laurenzi, 2001).  
These factors are extremely important to monitor during knockout of gene TGM2 coding 
for tTG as they are signals of the organism’s viability post-tTG knockout.   
Effects of tTG Silencing 
Nanda et al. has shown that tTG -/- transgenic mice were phenotypically normal 
in all regards, showing expected Mendelian genetics, normal weight and birth size, open 
eyes, properly formed fingers, and visible functionality of developmental apoptosis.  
Transgenic tTG -/- mice have also been shown to be fully capable of reproducing fertile 
offspring (Melino & De Laurenzi, 2001).  
While tTG is the principle agent of the vast majority of CD inflammation, the 
exact role and extent of zonulin, tight junction disassembly, and IEL activation via IL-15 
release leading to cellular damage is not confirmed.  Admittedly, tTG knockout, even if 
100% effective would not prevent all CD-based cellular damage.  However, zonulin 
release creates permeations only in the epithelial cells of the brush border, and without 
active tTG to continue the cascade in the lamina propria, damage would be limited to 
only these cells.  
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To determine the extent of zonulin’s action in CD pathology, I would suggest 
performing the following experiment before beginning tTG gene therapy trials.  Using 
HLA-DQ2 +/+ transgenic mice, I suggest up- and downregulating zonulin, noting 
changes in intestinal architecture to determine if increased levels produce more villous 
atrophy and scalloping of the intestinal wall and if decreased levels stimulate intestinal 
regeneration or halt disease progression compared to controlled non-zonulin-altered 
HLA-DQ2 +/+ mice. 
 Firstly, HLA-DQ2 +/+ mice must be created as it is essential that they: 1) express 
CD gluten intolerance and 2) express these symptoms through at least a partially tTG-
mediated immune response.  Zonulin levels may be regulated either by producing 
“zonulin encoding gene” (ZEG) modified transgenic mice, or through administration of 
known zonulin inhibitors or activators.   
 To determine if upregulation of zonulin increases cellular damage in mice 
expressing CD, zonulin protein production may be stimulated through the creation of 
transgenic mice overexpressing zonulin, or through the administration of zonula 
occludens toxin of Vibrio cholera, a known zonulin activator and mediator of tight 
junction disassembly.  Differences in small bowel architecture compared to control 
groups of HLA-DQ2 +/+ mice with non-altered zonulin levels should be noted.  
Similarly, downregulation of zonulin may be achieved through inhibition of ZEG through 
a Cre-lox excision system or similar interruption of the transcription of ZEG.  Differences 
in small bowel architecture compared to control groups of HLA-DQ2 +/+ mice with non-
altered zonulin levels should be noted.   
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The above study would hopefully produce unequivocal results aiding in the 
clarification of the exact role of zonulin in CD inflammation.  Speculating further, if the 
results were to suggest zonulin does indeed hold a major role CD inflammation, it would 
follow that the practicality of a zonulin and tTG siRNA co-delivery should be 
investigated. 
siRNA Transfection to Silence tTG Expression  
Overview 
 Short interfering RNA (siRNA) is double stranded RNA (dsRNA) 20-25bp in 
length.  siRNA binds to complementary nucleotide sequences in DNA to prevent mRNA 
and subsequent protein expression.  siRNA is produced biologically by the enzyme 
DICER, as it cuts long dsRNA into fragments; siRNA may also be manufactured 
synthetically for any given gene and then injected into the target cell.  However, siRNA 
is degraded rapidly by the innate immune response and intracellularly via enzymatic 
degradation.  Furthermore, large doses of siRNA appear to the body as a viral infection 
and may trigger the innate immune response.  It is therefore extremely important to 
develop a delivery vehicle for siRNA transfections that has no immunogenicity and is 
equally non-toxic to the host cells (“RNA interference (RNAi),” 2012). 
 Considering the aforementioned stability of mammals lacking tTG, it follows that 
the silencing of tTG in patients with CD may be a viable treatment.  Using the DNA 
sequence of tTG (Liu, Cerione, & Clardy, 2002), I suggest that siRNA be synthetically 
produced to match the TGM2 coding region to prevent tTG expression and remove the 
main agent of CD symptomology.  Transfections of siRNA into higher mammalian 
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vertebrates has been successful, showing 9-25 fold reductions in protein expression 
(Elbashir et al., 2001).  The ß-cyclodextrin nanopolymer complex designed by Davis, et 
al. will serve as the delivery vehicle as it: 1. Presents no immunogenicity, 2. Is virtually 
non-toxic to host cells in vivo and finally, 3. Is the only transfection reagent approved for 
pharmaceutical drug use (Sporanox), and proven to be viable for macromolecule 
transfection in humans.  
Delivery Vehicle 
Cyclodextrin is a cup shaped molecule formed of cyclic oligomers of glucose, 
with six, seven, or eight units representing α, ß, and γ forms respectively.  Cell toxicity is 
very low, measuring at 200mg/kg bodyweight, compared to 30mg/kg of polyethylene 
imidazole (PEI), a nanoparticle delivery vessel widely explored before cyclodextrin 
synthesis (Gonzalez, Hwang, & Davis, 1999).  The cyclodextrin polymer designed for 
siRNA transfection in humans, dubbed CALAA-01, is composed of four units: the 
siRNA cargo, the ß-cyclodextrin encapsulating shell, adamantine-polyethylene glycol 
(AD-PEG), and adamantine-polyethylene glycol Transferrin (AD-PEG-Tf), the 
previously mentioned AD-PEG chain with a human transferrin protein attached.  The ß-
cyclodextrin shell protects the siRNA from enzymatic degradation and from triggering 
innate immune responses.  Its structure and charge also allow it to pass through cellular 
membranes.  AD-PEG is used to increase stability in biological fluids, while AD-PEG-Tf 
is used as a cell-surface receptor signaling molecule to initiate uptake in targeted cells 
only.  In this case, human transferrin would be replaced with a targeting protein specific 




Figure 3.  ß-Cyclodextrin with bound AD-PEG and AD-PEG-tf vehicle for siRNA 
transfection (Alabi, Vegas, & Anderson, 2012).  ß-cyclodextrin is the nanopolymer 
encapsulating the siRNA.  Adamantane-polyethylene glycol (AD-PEG) is used to 
promote stability in biological fluids.  Adamantane-polyethylene glycol-transferrin (AD-
PEG-Tf) is a cellular surface receptor signaling protein for specific cellular uptake. 
 
Target Specificity 
Produced in intestinal epithelia and in the lamina propria, CXCR3 is a CXC-type 
7-transmembrane chemokine receptor.   These receptors are capable of binding specific 
8-10 kDa chemokines.  These receptors are also found on NK and T-cells and are used to 
stimulate chemotaxis and the inflammatory response (Baugher & Richmond, 2009).  
Besides binding chemokines, CXCR3 binds gliadin and is partially responsible for 
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initiating the aforementioned zonulin cascade to cause tight junction disassembly 
(Lammers et al., 2008).  Of the chemokines that bind to CXCR3, the chemokine ligand 
CXCL11 has the highest binding affinity (Trotta, Costantini, & Colonna, 2009).  To 
target enterocytes involved in the gliadin based inflammation, CXCL11 should be 
attached to the AD-PEG construct to select for enterocytes expressing CXCR3. 
However, as CXCR3 is also expressed in T-cells, an AD-PEG-CXCL11 targeting 
system would not select exclusively for enterocytes.  The role of tTG in NK and T-cells 
would need to be further examined in order to ensure the safety of CXCL11 as a targeting 
protein.  As an alternative, α-gliadin could also be bound to the vehicle.  As the method 
of gliadin absorption is still only partially understood at best, with CXCR3 receptors 
serving only a partial role in initiating CD signaling pathways, binding gliadin directly to 
the vehicle would ensure delivery into all cells affected by CD.  Furthermore, gliadin 
binding with CXCR3 is nowhere near the strength of its target chemokines, making its 
binding affinity outside of the intestinal environment extremely unlikely.  While little 
evidence exists documenting the relative binding strength and affinity of gliadin to 
CXCR3, its unequivocal role as the primary solicitor of CD symptomology makes it the 
ideal candidate for cell-specific targeting.  Additionally, the binding of gliadin to the 
delivery vehicle would likely render it non-toxic as it would be incapable of binding to 
intracellular enzymes due to the size of the vehicle to which it is attached. 
Clinical trials in siRNA transfections for gene silencing using ß-cyclodextrin as a 
delivery vehicle are already underway and have shown great promise. Biopsies of clinical 
trial patients have shown targeted mRNA fragments, lowered target protein expression, 
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and treatment efficacy lasting more than several dosing cycles.  Administration of 
CALAA-01 coated siRNA would be performed per the specifications of Davis, et al., at 
18, 24, and 30 mg siRNA/m
2
 via 30 minute intravenous injection on days 1, 3, 8, and 10 
of a 21 day cycle.   
While knockout of tTG expression throughout the human body could still produce no 
phenotypic differences, limitation of knockout to the afflicted cells of the small intestine 
will minimize potential risk and prevent unnecessary waste of siRNA cargo.    In all, 
siRNA transfections present a completely untapped resource to greatly improve the lives 
of nearly 43 million people worldwide.  Current treatment plans do nothing more than 
restrict lifestyle choices and ultimately doom the patient to unhappiness and discontent 
with their diet.  A radical treatment plan is the only option available for this disease; 
while some might argue for supplemental intake of enzymatic inhibitors, gene knockout 
would be far more effective, longer lasting, and specific than any other proposed 
treatment plan. 
Case Study 
 The following case study is of a 23 year-old Italian-American female who brought herself 
into her doctor’s office concerned for amenorrhea and an antebrachial rash.  The purpose of this 
case study is to illustrate the extraintestinal symptoms that may appear as secondary effects to 







Patient Name: Portia Catonis  Sex: Female  DOB: 03/15/1989 
Site of Visit: Family Practice Office    Date Of Visit: 04/01/2013 
Chief Complaint (CC) 
 Missed period last two months 
 Rash 
History of Present Illness (HPI) 
Ms. Portia Catonis is a 23 year old Italian-American female who brought herself 
into her general physician’s office on April 1
st
, 2013, expressing concern for missing her 
period for the last two months and for a persistent, red, itchy, blistery rash on her elbows.  
She admits to being sexually active with a single partner, but states that her partner 
always uses a condom.  While she reports having felt the “usual signs and symptoms” of 
a coming period, Ms. Catonis has not menstruated since 1/28/2013.  She denies any 
change in appetite or diet, but has lost about five pounds since the beginning of the year.  
The patient claims good emotional health and normal stress levels, but does notice that 
she feels less rested than normal upon arising.  Her hair seems drier and “less healthy” 
than normal and her nails are chipping frequently.   
 The patient reports the rash on her elbows to be spotty dark red, with occasional 
small, blister-like bumps.  The rash started on 3/25/2013 with mild discoloration and has 
progressively worsened over the past week.  The rash is unbearably itchy and the patient 
reports taking 25mg of diphenhydramine every four to six hours, providing her with 
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moderate relief.  She denies having changed bath or body products.  She does report 
having begun adding a laundry detergent booster around the time the rash appeared, but 
discontinued its use three days ago. 
Past Medical History (PMH) 
Ms. Catonis reports seasonal hay fever, with her worst allergies stemming from 
flower pollen and alfalfa.  Suffering from frequent colds as a child, she had her tonsils 
removed in 07/1997 at Saint Mary’s Hospital in Reno, NV.  The procedure had no 
complications and the patient was discharged the same day, recovering fully within a 
week.   The patient and her two brothers all contracted varicella at the same time as 
children in the winter of 1994. Ms. Catonis takes no medications and her immunizations 
are all current. 
Family History (FH) 
 The patient’s mother and father, aged 53 and 55, are both alive.  Her father has 
type I diabetes mellitus, mild hypercholesterolemia and hypertension.  Her mother was 
diagnosed with hypothyroidism five years ago, is lactose intolerant and has a “weak 
stomach”.  Her two male twin siblings, aged 21, are of good health and extremely active.  
Her paternal grandfather died this year of a heart attack, having both coronary heart 
disease and atherosclerosis.     
Social History (SH) 
 The patient is sexually active and monogamous.  She has been with her partner 
for almost two years.  She admits to several instances of unsafe sex, but denies previous 
STI’s, pregnancies, or use of hormonal birth control.  She drinks socially, 1-2 drinks on 
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one weekend night per week.  She denies tobacco or illicit drug use.  Ms. Catonis is 
regularly active, taking a one hour yoga classes two times per week.  The patient reports 
high stress levels from working and going to school, but states that the regular exercise 
helps to control it.  
Review of Systems (ROS) 
General: The patient reports decreased energy upon awakening and minor (<5 lbs.) 
weight loss.  The patient denies recent trauma, changes in appetite, fever, or sleep 
disturbance.  
Integumentary:  Patient reports a red, blotchy, itchy, raised rash on both arms, ranging 
5cm in each direction from elbow.  Denies breast pain, lumps, or discharge. 
HEENT: 
 Head: Denies trauma or headache 
 Ears: Denies tinnitus, changes/loss of hearing, or dizziness 
 Eyes: Denies changes/loss of vision, diplopia, discharge, or red eye 
 Nose:  Reports mild typical sinus congestion with little to no pain, dryness of the nasal 
membranes, denies epistaxis 
 Throat: Denies pain, dryness, odynophagia or dysphagia 
Neck:  Denies swelling or masses. 
Cardiovascular: Denies chest pain, palpitations, or generalized edema. 




Gastrointestinal: The patient reports a <5 lbs. weight loss but denies any changes in 
activity, diet, or behavior.  Denies abdominal pain, dyspepsia, nausea, or changes in 
appetite.   
Genitourinary: Reports amenorrhea for past two months.  Patient has experienced 
typical premenstrual-type symptoms such as bloating, emotional instability, acne, and 
muscle and breast tenderness without menstruation.  She also reports occasional spotting 
and diarrhea.  She states her last period was lighter than normal.  She denies dysuria, 
constipation, or incontinence.  No history of pregnancy, abortion, or miscarriage. 
Musculoskeletal: Denies pain, misalignment, joint swelling, or decreased range of 
motion.  
Neurological/Psychiatric: Denies headache, dizziness, loss of consciousness, 
paraesthesia, numbness, speech problems, loss of motor control, or changes in senses.  
The patient reports high stress and mild work-related anxiety.  She denies depression, 




Table 3. Patient vital signs 
Height Weight BMI Temp 
5’4” 120 lbs. 20.6 97.5°F 
HR SpO2 BP RR 




General: Patient is calm and attentive.  Patient occasionally scratches her elbows. 
Integumentary: Red-purple mottled papulovesicular rash beginning over both elbows 
and extending onto the dorsal antebrachium, approximately 5cm wide by 10cm long.  
The skin is broken in several areas within the rash boundary.  The rash is contained to 
these two regions and appears nowhere else.  No cyanosis, although a slight pallor is 
noted.  Fingernails appear brittle and are flaking.  Hair appears dry and frayed.     
HEENT: 
 Head: Normocephalic, atraumatic 
 Ears: Bilateral tympanic membrane intact and reactive to light 
 Eyes: Pupils equally round and reactive to light and accommodation 
bilaterally, bilateral sclera anicteric, no conjunctivitis 
 Nose: Mucous membranes dry, slight erythema 
 Throat: Mucous membranes moist with slight erythema 
Neck: Supple, no jugular venous distention, no lymphadenopathy, and no carotid bruit. 
Cardiovascular: Regular rate and rhythm, S1 and S2 are normal with a slight flow 
murmur; no rubs, or gallops.  Point of maximum impulse non-displaced and non-
sustained.  No hepatojugular reflux. Capillary refill is approximately 3 seconds. 




Abdomen: Soft, non-distended and non-tender.  No rebound or guarding observed.  No 
pulsatile masses present.  Normal bowel sounds are present in all four quadrants, along 
with resonant percussion.  No costovertebral angle tenderness. 
Genitourinary: No labial/external swelling, erythema, or lesions.  No tenderness, 
discharge, or odor observed.  Vaginal walls and cervix are intact with no lesions but show 
slight pallor and dryness.  The uterus is anteverted, free of masses and non-tender.  
Bimanual palpation elicited no cervical motion tenderness, vaginal bleeding, discharge, 
or masses.  Ovaries and fallopian tubes non-palpable. 
Musculoskeletal: Normal range of motion, no joint swelling or erythema. 
Nuerological/Psychiatric: Cranial Nerve II-XII intact, no focal deficit present.  Normal 












Table 4. Complete Blood Count with Differential 
ITEM UNIT VALUE REFERENCE  
WBC Count X10
9
/L 7.8 4.0-11.0 N 
Neutrophils % 2.5 2.0-7.5 N 
Lymphocytes % 3.0 1.0-4.5 N 
Monocytes % 0.62 0.2-0.8 N 
Eosinophils % 0.12 0.04-0.40 N 
Basophils % <0.1 <0.1 N 
RBC Count X10
6
/µL 4.2 3.9-5.03 N 
Hematocrit % 33.0 34.9-44.5 L 
Hemoglobin g/dL 11.0 12.0-15.5 L 
Mean Corpuscular Volume fL 78.6 82.0-98.0 L 
Mean Corpuscular Hemoglobin pg 26.2 26.0-34.0 N 
Mean Corpsucular Hemoglobin 
Concentration 
g/dL 33.3 32.0-36.0 N 
Red Blood Cell Distribution Width % 12.3 11.5-14.5 N 





Mean Platelet Volume fL 7.9 7.4-10.4 N 
 
Table 5. Serum Iron Panel 
ITEM UNIT VALUE REFERENCE  
Serum Iron µg/dL 41 50-170 L 
TIBC µg/dL 550 240-450 H 
Transferrin 
Saturation 









Table 6. Comprehensive Metabolic Panel 
ITEM UNIT VALUE REFERENCE  
Glucose mg/dL                                                                                                                     90 65-99 N
Urea Nitrogen (BUN) mg/dL                                                                                                                     21 7-25 N
Creatinine mg/dL                                                                                                                     1.29 0.78-1.34 N
eGFR Non-Afr. American ml/min/m
2
 65 >or=60 N 
eGFR African American ml/min/m
2
  >or=60  
BUN/Creatinine Ratio  16  6-22 N 
Sodium mmol/L 141 135-146 N 
Potassium mmol/L 2.9 3.5-5.3 L 
Chloride mmol/L 88 98-110 L 
Calcium mg/dL 8.2 8.6-10.2 L 
Carbon Dioxide mmol/L 23 21-33 N 
Protein, Total g/dL 5.6 6.2-8.2 L 
Albumin g/dL 3.1 3.5-5.0 L 
Globulin g/dL 2.4 2.1-3.7 N 
Albumin/Globulin Ratio  1.29 1.0-2.1 N 
Bilirubin, Total mg/dL                                                                                                                     0.9 0.2-1.2 N
Alkaline Phosphatase U/L 66 40-115 N 
AST U/L 23 10-40 N 
ALT U/L 42 9-60 N 
 
Table 7. Thyroid Stimulating Hormone Panel 
ITEM UNIT VALUE REFERENCE  
TSH mU/L 2.2 0.4-4.2 N 
 
Table 8. Human Chorionic Gonadotropin Panel  
ITEM UNIT VALUE REFERENCE  
hCG mIU/ml 2.2 <5.0  Non-pregnant 
 
Table 9. Anti-IgA Antibodies Panel 




U/mL 16 <4 H 




Video Capsule Endoscopy 
     
a)                                                                 b) 
    
c)                                                                    d) 
Figure 4. Video capsule endoscopy. Video capsule endoscopy showed abnormal jejunal 
architecture.  a) scalloping of the intestinal wall; b) mosaic patterning; c) 







Figure 5.  Jejunal biopsy. The jejunal biopsy demonstrates marked villous blunting, 
early crypt hyperplasia, and excessive lymphocyte infiltration into the villous tips 
(Schenk, Samloff, & Klipstein, 1965). 
 
Assessment 
Ms. Portia Catonis shows low hematocrit, hemoglobin, and mean corpuscular 
volume, suggesting anemia.  Further analysis of serum iron elucidates a high probability 
of simple iron deficiency anemia, noted by decreased serum iron and transferrin 
saturation along with increased total iron binding capacity.  Low ion levels including 
potassium, chloride, and calcium were observed, in addition to low total serum protein 
and albumin levels.  These factors in concert with the patient’s reported fatigue, weight 
loss, and weak hair/nails support the conclusion of a malabsorptive issue.  Human 
chorionic gonadotropin levels were not elevated, verifying the patient is not pregnant.  
Anti-IgA antibodies were present, strongly suggesting the presence of celiac disease.  
Video capsule endoscopy and a jejunal biopsy confirmed celiac pathology.  Celiac 
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disease and dermatitis herpetiformis were determined as the root causes of the patient’s 
amenorrhea and antebrachial rash. 
Diagnosis 
 Celiac disease induced amenorrhea 
 Simple iron deficiency anemia 
 Dermatitis herpetiformis 
Treatment 
Ms. Catonis was instructed to begin a gluten-free diet and was explained food 
restrictions, alternatives, and advised to purchase several gluten-free cookbooks.  She was 
given 1% hydrocortisone cream to be applied to the rash three to four times daily to 
control itching.  She was instructed to return to the clinic in two months for follow-up 
serological evaluation and to return again if her period does not resume within four 
months.  The patient was referred to a gastroenterologist for monitoring and control of 










 The difficulty in treating gluten intolerance lays not in the disease itself, but rather 
the near-omnipresence of gluten in American diets.  The world has made inconceivably 
large changes in the past fifty years; technology, medicine, finances, and the arts have all 
benefitted from our global community.  In the face of what we have achieved, it is 
shameful that we have yet to come up with a better solution to CD than “don’t eat 
wheat”.  
 Admittedly, CD does present some complications.  Its illusive polyfactorial nature 
leaves many questions unanswered.  The redundant role of the HLA-DQ proteins begs 
the question: “what then is necessary?”  Genetic screening is only partially accurate 
considering the HLA-DQ family, and serological evaluation is not conclusive, requiring 
either invasive procedures or the inconvenience of a gluten-free diet to “trial and error” 
diagnose the patient.  Nonetheless, the lack of new treatments which provide our patients 
with the highest level of care possible stems not from our knowledgebase, but rather from 
our imagination. 
 While ß-cyclodextrin based vehicles are only starting their clinical trials process, 
they hold far more promise in successful siRNA delivery than any previous non-viral 
method researched to-date.  With the long-term goal of siRNA transfection treatments 
being gene knockouts lasting between years and a lifetime, treatment dosing and 
specificity are the highest priority to ensure the greatest uptake of siRNA into target 
intestinal cells.  To create optimal specificity, development of an appropriate cell surface 
ligand for the ß-cyclodextrin vehicle should be secondary in focus only to continuing 
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confirmation of the stability of ß-cyclodextrin.  So far, stability in biological fluids and 
target specificity have been exceedingly positive; the likelihood of developing a non-
cytotoxic, specific, and effective uptake protocol for siRNA within the next five to ten 
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